Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, expanding the trial's European reach in the largest TAVR market. The PARADIGM trial compares DurAVR to existing TAVR devices in about 1,000 patients to assess safety and effectiveness. Germany's inclusion is expected to accelerate enrollment and strengthen the trial's impact in international heart valve markets.
Anteris Technologies' PARADIGM trial expansion in Germany is the subject, with Pluang's health sector market data providing context. As of Oct 20, 2026 08:51 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 83 rose and 66 fell. Notable movers include TNGX at USD 23.58 with a 6.99% increase, SMMT at USD 15.53 up 6.15%, and SYRE at USD 84.71 rising 6.02%.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
Flipkart, owned by Walmart, is launching a food delivery service in India to compete against dominant players Zomato and Swiggy. The company is currently testing the service internally in Bengaluru with plans for a public launch by October and expans...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
